News

New Screening Tool for Osteoporosis – Osentia® test will enable people to assess their risk of suffering a fragility fracture

10 March 2014 … Crescent Diagnostics Ltd (“Crescent”) has launched Osentia®, a new convenient screening test which identifies those at risk of fragility fracture by analysing finger or toe nail clippings. Launching in the UK, Osentia® is available online and will … more

Crescent Diagnostics appoints Barry Clare as Chairman

9 September 2013 … Crescent Diagnostics Ltd (“Crescent”), a developer of novel tests for predicting osteoporotic fracture risk, is pleased to announce the appointment of Barry Clare as Chairman. Barry was previously a main board director at The Boots Company … more

Crescent announces start of fundraising

2 July 2013 Crescent is currently undertaking a fundraising exercise and is seeking Euro 3 million to support the launch of Osentia in the UK and republic of Ireland

Crescent set to attend Pharmacy Show

31 July 2013 Crescent  Diagnostic will have a stand  at the biggest and most important business and clinical event on the pharmacy calendar – The Pharmacy Show, Sunday 29th & Monday 30th September 2013 at NEC, Birmingham. Members of Crescent’s … more

Crescent shortlisted for Innovators Den award

7 March 2013 Crescent Diagnostics, a medical technology company which is developing a novel osteoporosis screening tool, has been shortlisted for the Innovators Den at the Healthcare Innovations Expo 2013 in London. The event will see Crescent present to a … more

Invest NI supports development of Crescent Diagnostics’ breakthrough diagnostic test

14 May 2012 Clinical diagnostics company, Crescent Diagnostics Ltd (Crescent), is to set up a research and development project in Londonderry to develop a predictive test for osteoporosis. The company is headquartered at NovaUCD, Dublin and has a lab at … more

Crescent Diagnostics Appoints Brendan K. Farrell as Chief Executive Officer

4th April 2012 Dublin, Ireland, 4th April 2012, Crescent Diagnostics Ltd (“Crescent”), a medical diagnostics company, which has developed a proprietary predictive test for osteoporosis, today announced the appointment of Brendan K. Farrell as CEO. Brendan has over 30 years international experience … more

Crescent Diagnostics Secures Euro 1.5 Million ($2.2 Million) for Its Predictive Test for Osteoporotic Fracture

Funding to Support Additional Clinical Testing for Regulatory Approvals in the U.S. and E.U. Dublin, Ireland: 22nd June 2011… Crescent Diagnostics Ltd, (“Crescent”) a developer of novel tests for predicting osteoporotic fracture risk, today announced that it has raised Euro … more

Crescent Diagnostics Wins Prestigious Medical Technology Industry Award

Dublin, December 2, 2010 - Crescent Diagnostics was last night awarded gold in the ‘Innovation, Research, Development and Commercialisation’ category at the fourth annual Medical Technology Industry Excellence Awards, jointly hosted by Enterprise Ireland, IDA Ireland and the Irish Medical Devices … more